微量白蛋白尿在ICU中的研究进展

Research Advancement of Microalbuminuria in ICU

微量白蛋白尿(MAU)是评价早期肾脏病变和全身内皮系统病变的敏感指标,且可作为肾功能不全和心血管疾病发病率及病死率的独立预测因子。将MAU应用于重症监护(ICU)患者具有理论上的依据。通过对MAU水平的检测,可评价ICU患者肾脏病变、心脑血管病变、急性肺损伤、全身炎性反应综合征、多器官功能障碍综合征等疾病严重程度并预测预后,以便尽早采取有针对性的干预措施以改善预后。

Microalbuminuria has been established as a sensitive index to assess the early stage of renal disease and systemic endothelial dysfunction, which is also recognized as an independent predictor of the morbidity and mortality of renal failure and cardiovascular events. There are theoretical reasons why this parameter may be a useful prognostic index in critically ill patients admitted to the ICU. It will be helpful for clinic to evaluate illness severity and to predict prognosis such as renal disease, cerebral, cardiovascular events, ALI, SIRS, MODS and so on. So that the accurate and aggressive clinical intervention can be taken earlier to improve prognosis of patients.